Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been given an average rating of “Buy” by the eleven ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $21.33.

Several analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a research note on Friday, May 26th. They set a “buy” rating and a $18.00 price target for the company. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. BidaskClub lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Piper Jaffray Companies set a $23.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. set a $21.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd.

A number of institutional investors have recently modified their holdings of VNDA. The Manufacturers Life Insurance Company raised its position in shares of Vanda Pharmaceuticals by 20.3% in the second quarter. The Manufacturers Life Insurance Company now owns 34,882 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 5,875 shares during the last quarter. State Street Corp raised its position in Vanda Pharmaceuticals by 2.9% in the second quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock valued at $26,380,000 after buying an additional 46,299 shares in the last quarter. Gotham Asset Management LLC raised its position in Vanda Pharmaceuticals by 3.6% in the second quarter. Gotham Asset Management LLC now owns 173,923 shares of the biopharmaceutical company’s stock valued at $2,835,000 after buying an additional 5,970 shares in the last quarter. Macquarie Group Ltd. raised its position in Vanda Pharmaceuticals by 8.8% in the second quarter. Macquarie Group Ltd. now owns 1,703,559 shares of the biopharmaceutical company’s stock valued at $27,768,000 after buying an additional 138,278 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its position in Vanda Pharmaceuticals by 1,482.2% in the second quarter. Stonepine Capital Management LLC now owns 685,086 shares of the biopharmaceutical company’s stock valued at $11,167,000 after buying an additional 641,786 shares in the last quarter. 90.84% of the stock is currently owned by institutional investors.

Shares of Vanda Pharmaceuticals (NASDAQ VNDA) traded down 0.31% during mid-day trading on Tuesday, hitting $16.05. The stock had a trading volume of 28,255 shares. The stock’s market cap is $719.97 million. The company’s 50 day moving average is $16.17 and its 200-day moving average is $14.74. Vanda Pharmaceuticals has a 52-week low of $11.58 and a 52-week high of $18.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. During the same quarter in the previous year, the firm posted $0.01 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. On average, equities research analysts anticipate that Vanda Pharmaceuticals will post ($0.52) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Recommendation of “Buy” from Brokerages” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/vanda-pharmaceuticals-inc-vnda-receives-consensus-recommendation-of-buy-from-brokerages/1490863.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.